Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARγ) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages 599-610

  Lado Abeal, J ^a,b   Celestino, R ^c   Bravo, S B ^a   Garcia Rendueles, M E R ^a   De La Calzada, J ^d   Castro, I ^a   Castro, P ^c   Espadinha, C ^e   Palos, F ^a   Soares, P ^c   Alvarez, C V ^a   Sobrinho Simoes M ^c   Cameselle Teijeiro, J ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^e INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IODINE 131; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RNA; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR PAX8; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN;

ADULT; ARTICLE; CASE REPORT; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHYROIDISM; LEIOMYOMA; LYMPHOCYTE; MOSAICISM; POLYMERASE CHAIN REACTION; THYROID CARCINOMA; THYROID CELL; THYROID FOLLICULAR CARCINOMA; TUMOR GROWTH; UTERUS TUMOR; ADENOCARCINOMA; GENE REARRANGEMENT; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; MUTATION; THYROID TUMOR; WESTERN BLOTTING;

ADENOCARCINOMA, FOLLICULAR; BLOTTING, WESTERN; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; MOSAICISM; MUTATION; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; RECEPTORS, THYROTROPIN; THYROID NEOPLASMS;

EID: 77956223649     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0069     Document Type: Article

References (37)

1. Au AYM, McBride C, Wilhelm KG Jr, Koenig RJ, Speller B, Cheung L, Messina M, Wentworth J, Tasevski V, Learoyd D et al. 2006 PAX8-perosisome proliferator-activated receptor γ (PPARγ) disrupts normal PAX8 or PPARγ transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 147 367-376.
2. Bernards A & Gusella JF 1994 The importance of genetic mosaicism in human disease. New England Journal of Medicine 331 1447-1449.
3. Bravo SB, Pampin S, Cameselle-Teijeiro J, Carneiro C, Dominguez F, Barreiro F & Alvarez CV 2003 TGF-beta- induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-kappaB activation. Oncogene 22 7819-7830. (Pubitemid 37485541)
4. Bravo SB, Garcia-Rendueles ME, Perez-Romero S, Cameselle-Teijeiro J, Rodrigues JS, Barreiro F & Alvarez CV 2010 Expression of exogenous proteins and short hairpin RNAs in human primary thyrocytes. Analytical Biochemistry 400 219-228.
5. Camacho P, Gordon D, Chiefari E, Yong S, DeJong S, Pitale S, Russo D & Filetti S 2000 A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism. Thyroid 10 1009-1012. (Pubitemid 32104088)
6. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P & Sobrinho-Simões M 2009 Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. American Journal of Clinical Pathology 131 134-142.
7. Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P et al. 2006 PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 91 213-220. (Pubitemid 43069140)
8. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG & Shenker A 2003 Thyroid carcinoma in the McCune-Albright syndrome: a contributory role of activating Gsalpha mutations. Journal of Clinical Endocrinology and Metabolism 88 4413-4417. (Pubitemid 37153751)
9. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A & Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Journal of Clinical Endocrinology and Metabolism 93 3943-3949.
10. Fuhrer D, Tannapfel A, Sabri O, Lamesch P & Paschke R 2003 Two somatic TSH receptor mutations in a patient with a toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. Endocrine-Related Cancer 10 591-600. (Pubitemid 38094893)
11. Gozu H, Avsar M, Bircan R, Sahin S, Ahiskanali R, Gulluoglu B, Deyneli O, Ones T, Narin Y, Akalin S et al. 2004 Does a Leu 512 Arg thyrotropin receptor mutation cause an autonomously functioning papillary carcinoma? Thyroid 14 975-980.
12. Houston KD, Copland JA, Broaddus RR, Gottardis MM, Fischer SM & Walker CL 2003 Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma. Cancer Research 63 1221-1227.
13. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306.
14. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM & Fletcher JA 2005 PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289 1357-1360.
15. Ludgate M, Gire V, Crisp M, Ajjan R, Weetman A, Ivan M & Wynford-Thomas D 1999 Contrasting effects of activating mutations of GalphaS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells. Oncogene 18 4798-4807.
16. Majima T, Doi K, Komatsu Y, Itoh H, Fukao A, Shigemoto M, Takagi C, Corners J, Mizuta N, Kato R et al. 2005 Papillary thyroid carcinoma without metastases manifesting as an autonomously functioning thyroid nodule. Endocrine Journal 52 309-316.
17. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG & Leite V 2002 Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. Journal of Clinical Endocrinology and Metabolism 87 3947-3952.
18. Marques AR, Espadinha C, Frias MJ, Roque L, Catarino AL, Sobrinho LG & Leite V 2004 Underexpression of peroxisome proliferator-activated receptor (PPAR)- gamma in PAX8/PPARgamma-negative thyroid tumours. British Journal of Cancer 91 732-738.
19. Matsuo K, Friedman E, Gejman PV & Fagin JA 1993 The thyrotropin receptor (TSH-R) is not an oncogene for the thyroid tumors: structural studies of the TSH-R and the alpha-subunit of the Gs in human thyroid neoplasms. Journal of Clinical Endocrinology and Metabolism 76 1446-1451. (Pubitemid 23164359)
20. Mircescu H, Parma J, Huopt C, Deal C, Oligny LL, Vassart G & Van Vliet G 2000 Hyperfunctioning malignant thyroid nodule in an 11-year-old girl: pathologic and molecular studies. Journal of Pediatrics 37 585-587.
21. Mittag J, Winterhager E, Bauer K & Grümmer R 2007 Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 148 719-725. (Pubitemid 46143173)
22. Niepomniszcze H, Suaez H, Pitoia F, Pignatta A, Danilowicz K, Manavela M, Elsner B & Bruno OD 2006 Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid 16 497-503. (Pubitemid 43912154)
23. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG & Nikiforov YE 2002 PAX8-PPARγ rearrangement in thyroid tumors. American Journal of Surgical Pathology 26 1016-1023.
24. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW II, Tallini G, Kroll TG & Nikiforov YE 2003 RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism 88 2318-2326. (Pubitemid 36549913)
25. Palos F, García-Rendueles ME, Araujo-Vilar D, Obregon MJ, Calvo RM, Cameselle-Teijeiro J, Bravo SB, Perez-Guerra O, Loidi L, Czarnocka B et al. 2008 Pendred syndrome in two Galician families: insights into clinical phenotypes through cellular, genetic, and molecular studies. Journal of Clinical Endocrinology and Metabolism 93 267-277.
26. Palos-Paz F, Perez-Guerra O, Cameselle-Teijeiro J, Rueda-Chimeno C, Barreiro-Morandeira F, Lado-Abeal J & Galician Group for the Study of Toxic Multinodular Goitre 2008 Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. European Journal of Endocrinology 159 623-631.
27. Paul JP & Sisson JC 1990 Thyrotoxicosis caused by thyroid cancer. Endocrinology and Metabolism Clinics of North America 19 593-612.
28. Reddi HV, McIver B, Grebe SKG & Eberhardt NL 2007 Minireview: the paired box-8/peroxisome proliferator- activated receptor-gamma oncogene in thyroid tumorogenesis. Endocrinology 148 932-935. (Pubitemid 46272776)
29. de Roux N, Polak M, Couet J, Leger J, Czernichow P, Milgrom E & Misrahi M 1996 A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 81 2023-2026. (Pubitemid 26175920)
30. Russo D, Arturi F, Schlumbarger M, Caillou B, Monier R, Filetti S & Suarez HG 1995 Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene 11 1907-1911.
31. Russo D, Tumino S, Arturi F, Vigneri P, Grasso G, Pontecorvi A, Filetti S & Belfiore A 1997 Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. Journal of Clinical Endocrinology and Metabolism 82 735-738. (Pubitemid 27106579)
32. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SK et al. 2005 PPARγ staining as a surrogate for PAX8/PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. Journal of Clinical Endocrinology and Metabolism 90 463-468.
33. Sobrinho-Simões M, Máximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J & Soares P 2008 Intragenic mutations in thyroid cancer. Endocrinology and Metabolism Clinics of North America 37 333-362.
34. Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros-Neto G & Fagin JA 1996 Structural studies of the thyrotropin receptor and Gsalpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. Journal of Clinical Endocrinology and Metabolism 81 3898-3901. (Pubitemid 26380393)
35. Suarez HG 2000 Molecular basis of epithelial thyroid tumorigenesis. Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie 323 519-528.
36. Vassar G & Dumont JE 1992 The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocrine Reviews 13 596-611.
37. Youssoufian H & Pyeritz RE 2002 Mechanisms and consequences of somatic mosaicism in humans. Nature Reviews. Genetics 3 748-758.